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Atopic dermatitis (AD) is a common inﬂammatory skin disease. The increasing prevalence and severity of AD have prompted
t h ed e v e l o p m e n t so fs a f e r ,m o r ee ﬀective drugs. Although topical corticosteroids have been used as ﬁrst line therapy for AD, their
potential side eﬀects limit their clinical applications. To investigate the eﬀect of hirsutenone (HIR), a diarylheptanoid compound,
on AD-like skin lesions and other factors related to immune response is the aim of this paper Th2-related cytokines (IL-4, IL-
5, IL-13), eosinophil, IgE inﬂammatory factors (COX-2, iNOS) levels were reduced in blood, lymphocytes, and tissue after HIR
treatment. These results suggest that HIR might be an eﬀective treatment for AD.
1.Introduction
Atopic dermatitis (AD) is a chronic relapsing skin disorder
with allergic inﬂammation. AD is one of the most common
skin diseases in children with a family history of atopy and
is frequently associated with elevated plasma levels of IgE
antibodies against inhaled allergens [1, 2]. The histology of
AD is characterized by epidermal alterations and a dermal
inﬂammatory inﬁltrate containing eosinophils [1]. The
causes of atopic dermatitis are not completely understood,
but a complex inﬂammatory immune dysregulation and
response to allergens are believed to be involved [2].
The most promising antiatopic dermatitis drugs are
compounds that are immune-suppressive. These topical
corticosteroids are the primary choice for AD treatment,
but their side eﬀects, such as, perioral dermatitis and skin
atrophy and striae in sensitive areas, are a major obstacle to
their long-term application [3].
Recently, we isolated diarylheptanoid compounds from
the bark of Alnus japonica [4]. The bark of Alnus japonica
is used in oriental traditional medicine to treat fever, hem-
orrhage, diarrhea, gastroenteric disorder, lymphatic disease,
and cancers [5]. The diarylheptanoids, which are charac-
teristic components of Alnus species, have been reported to
haveseveralbiologicalactivities.Inthisstudy,weinvestigated
HIR, a diarylheptanoid, which has previously been shown
to have inhibitory activity on cyclooxygenase-2 expression
and anti-inﬂammatory eﬀects [6–12]. Furthermore, HIR has
been reported to prevent cytokine and chemokine-mediated
immune cell function and inﬂammatory reaction and was2 Clinical and Developmental Immunology
found to be an attractive starting point for the development
of a topical drug for T cell-based anti-atopic dermatitis due
to its calcineurin inhibitory eﬀects [13, 14].
AD is frequently associated with elevated plasma levels of
IgE antibodies against many kinds of inhaled allergens [15,
16]. IgE-mediated mast cell activation leads to the release of
various chemical mediators, which results in the inﬁltration
of inﬂammatory cells, such as, eosinophils and lymphocytes,
into skin lesions. Moreover, when promoted by IL-5, IL-
4 is able to trigger IgE synthesis and IL-4-dependent IgE
synthesis in B cell [17]. In patients with AD, decreased
IFN-γ production is considered to be associated with IgE
hypersynthesis and Th2 immune response [18].
In the present study, we induced AD-like skin lesions
in NC/Nga mice by repeatedly applying Dermatophagoides
farina (House dust) containing cream. We then examined
whetherHIRhasanimmunemodulatingeﬀectinthismodel
and compared this with those of the established therapeutic
agents dexamethasone (DEX) and hydrocortisone cream
(HDC). The eﬃcacies of these test agents were evaluated
using clinical skin severity scores, cytokine (IL-4, IL-5, IL-
13) expression in blood and spleen, and total plasma levels of
IgE.Inanattempttoidentifythemolecularmodeofactionof
HIR,wealsoexamineditseﬀectontheexpressionsofCOX-2
and iNOS in skin.
2.MaterialsandMethods
2.1. Phytochemical
2.1.1. Extraction and Isolation of HIR. The bark of A. japon-
ica was collected at Mt. Sudal, Seoul, Republic of Korea
in June 2008, and a voucher specimen (AJB0806) was
deposited at the herbarium, College of Pharmacy, Chung-
Ang University. Bark (5.15kg) was extracted for 72h at room
temperature with 80% aqueous acetone. After removing the
acetone under vacuum, the aqueous solution was ﬁltered
through ﬁlter paper (Tokyo Roshi Kaisha Ltd, Japan), and
the ﬁltrate was concentrated and applied to a Sephadex LH-
20 column (10–25μm, GE Healthcare Bio-Science AB, Upp-
sala, Sweden), and eluted with H2O containing increasing
proportions of methanol to aﬀord 4 fractions, A (44.31g),
B (173.94g), C (2.12g), and D (6.8g). Repeated column
chromatography of fraction B (173.94g) on MCl-Gel CHP
20P (75–150μm, 5 × 80cm, Mitsubishi Chemical Co.,
Tokyo) using an H2O: methanol gradient yielded oregonin
(ORE) (39.99g).
2.1.2. Preparation of HIR by the Enzymatic Hydrolysis of
ORE. The ORE (1g, 1%, w/w) was diluted in distilled water
(940ml, 94%, w/w) and Pectinex AFP-L4 (polygalacturonase
from Aspergillus aculeatus or Aspergillus niger) (Nobozymes
Co. Ltd, Bagsvaerd, Denmark) (50ml, 5%, w/w) was added
[19, 20]. The mixture was then shaken aerobicallyat 150rpm
for 18 hours at room temperature, heated at 85
◦Cf o r5m i n
to inactivate the enzyme, and then centrifuged (3000rpm)
for 30min and ﬁltered. The ﬁltrate was fractionated with
ethyl acetate, and the ethyl acetate layer (0.63g) was applied
to a Sephadex LH-20 column and eluted with 60% MeOH to
yield HIR (0.252g).
2.1.3.ORE(1.7-bis-(3,4-Dihydroxy-Phenyl)-Heptane-3-on-5-
O-β-D-Xylopyranoside). Brown amorphous powder, Nega-
tive FAB-MS m/z: 477 [M-H]−, 1H-NMR, and 13C-NMR
data [21].
2.1.4.HIR(1,7-bis-(3,4-Dihydroxyphenyl)-4-Heptene-3-One).
Brown oil, Negative EI-MS m/z: 328 [M]+,1 H - N M R ,a n d
13C-NMR data [21].
2.2. Experimental Model
2.2.1. Induction of AD-Like Skin Lesions in NC/Nga Mice.
Thirty-ﬁve female NC/Nga mice aged 3 weeks were pur-
chased from SLC Tokyo (Tokyo) and maintained under con-
ventional conditions. Dermatophagoides farina (House dust)
containing cream was used to induce AD-like skin lesions.
The back fur of ether-anaesthetized animals was shaved oﬀ
using a hair clipper 1 week before sensitization. Induction
was performed 14 days after sensitization. Dermatophagoides
farina (House dust) containing cream was applied to backs
twice a week from 3 to 17 weeks [22, 23].
2.2.2. Treatment and Severity Scores. Phosphate Buﬀered
Saline (PBS), and 0.1% HIR and 1% HIR liquid solutions
were injected intraperitoneally, twice a week, and base cream
and 1% HIR topical creamwereapplied to exposed back skin
daily for 4 weeks.
Severity of dermatitis was assessed macroscopically in
a blinded fashion weekly using the following scoring pro-
cedure. Total clinical skin severity scores were deﬁned as
the sum of individual scores for the following ﬁve signs
and symptoms: itching, erythema, excoriation, scaling, and
dryness. Each of these items was allocated scores of 0–3,
where 0 = no symptoms, 1 = mild, 2 = moderate, and 3 =
severe, as described previously [23–25].
2.2.3. Measurement of Total IgE Level in Plasma. Blood
was collected from the retro-orbital plexus using hep-
arinized glass capillary tubes before and after treatment.
Plasma samples were obtained by centrifuging at 12,000rpm
f o r1 0 m i na n ds t o r e da t−80
◦C until required for
assay. Total plasma IgE levels were determined by enzyme-
linked immunosorbent assay (ELISA) using a method
involving the capture and detection of monoclonal anti-
body pairs, as suggested by BD Pharmingen (San Diego,
CA).
2.2.4. Eosinophil Count in Blood. Blood samples were col-
lected before and after treatment. Whole blood cell counts
were conducted on 30ul samples diluted sixfold with 150ul
of saline. Diﬀerential counts were determined by counting
under a microscope using Wring-Giemsa stained blood
smears. Eosinophil counts were calculated from diﬀerential
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2.2.5. Cytokine Assays in Splenocytes and Serum. Total
splenocytes were prepared and cells were plated at 1 × 106
cell/ml. Red blood cells were lysed using RBC lysis buﬀer
(Sigma, St. Louis). Lysates were centrifuged at 13,000rpm
for 15min at 4◦C. Supernatants were removed and cells
were seeded at 1 × 106 cell/ml and cultured in 24 well
plates. Supernatants containing cultured lymphocytes were
harvested. Blood samples were collected from aortas. Serum
samples were obtained by centrifuging at 13,000rpm for
10min and stored at −80
◦C until required for assay.
The supernatants of cultured splenocytes and serum were
analyzed for cytokine levels by ELISA.
2.2.6. Real-Time RT-PCR. Tissues from AD-like skin lesions
weresuspendedinTRIzolReagent(InvitrogenLifeTechnolo-
gies, Carlsbad, CA). Total RNA was extracted using TRIzol
reagent according to the protocol provided by the manu-
facturer (Invitrogen Life Technologies, Carlsbad, CA). Equal
amounts(2ug)oftotalRNAwereobtainedfromeachsample
and reverse transcribed into cDNA with oligo(dT)15 primers
usingM-MLVreversetranscriptase (Promega,Madison, WI)
at 42
◦C for 1h. Reaction mixtures were ampliﬁed using
a SYBRGreen Supermix (Bio-Rad, Hercules, CA) in the
presence of 1ul of the sense and of the antisense primers
of COX-2 and iNOS, and with primers for GAPDH using a
Cycler Real-Time PCR Detection system using the following
thermal cycling program, 30 times at 94
◦C for 30s, at 60
◦C
for 30s, and at 72
◦C for 40s. The sequences of the primers
used were as follows: mouse iNOS, 5 -ctgcctcttccaggtgt-3 
and 5 -gagggactttctgaatc-3 ; mouse COX-2, 5 -cccacccatggc-
aaattccatggca-3  and 5 -ggtgctgcttgttaggaggtcaagtaa-3 ;a n d
mouse GAPDH 5 -ccacccatggcaaattccatggca-3  and 5 -ccctg-
ttgctgtagccgtat-3 . The experiments were performed in trip-
licate and repeated at least three times.
2.2.7. Western Blot Analysis. Tissues from AD-like skin le-
sions weresuspendedin ProprepReagent(iNtRON, Kyunggi,
SN). Proteins were extracted using reagent according to the
protocol provided by the manufacturer (iNtRON, Kyunggi,
SN). After electrophoresis, proteins were transferred onto
nitrocellulose membranes, which were blocked with 5%
skim milk in Tris-buﬀered saline solution containing 0.1%
Tween-20. Immunoblotting with primary antibody, anti-
iNOS, and anti-COX-2 was followed by mouse anti-rabbit
peroxidase conjugated antibody (Chemicon). Blots were
developed using ECL solution.
2.2.8. Statistical Analysis. The results are expressed as mean
± SD. The paired t-test was used to compare two groups and
one-way ANOVA and Dunnett’s t-test were used for multiple
comparisons. The analysis was conducted using GraphPad
Prism software. Statistical signiﬁcance was accepted for P
value of < .05.
3. Results
3.1. HIR Suppressed the Development of AD-Like Skin Lesions
in NC/Nga Mice. NC/Nga mice has been shown to develop
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Figure 1: Chemical structures of oregonin and hirsutenone.
AD-like skin lesions after the repeated application Der-
matophagoides farina (House dust) containing cream. In
accordance with this previous ﬁnding, clinical severity in
the control PBS-injected and Base cream-treated NC/Nga
mice increased gradually with number of challenges and
reachedamaximumonday19aftersensitization.Mostofthe
mice expressed AD-like skin lesions characterized by itching,
erythema, excoriation, scaling, and dryness. The HIR, DEX,
and 0.1% HDC exhibited lesion suppression, and clinical
skin severity scores were signiﬁcantly diﬀerent in the control
group and HIR groups (∗P < .05 compared with the PBS
group. #P < .05 compared with the base group) (Figure 2).
3.2. HIR Signiﬁcantly Reduced Eosinophil Counts in Blood.
To investigate the eﬀect of HIR treatment, we counted
eosinophils in blood. The presence of eosinophils in the
inﬂammatory inﬁltrate of AD has long been established, and
thus blood was collected from the retro-orbital plexus. The
PBS and Base groups showed increases in eosinophil counts
before treatment. On the other hand, HIR signiﬁcantly
decreased eosinophil count after treatment commencement
(∗P < .05 compared with the PBS group. #P < .05 compared
with the base group) (Figure 3(a)).
3.3. HIR Modulated Total IgE Levels. We performed ELISA
to examine the eﬀe c to fH I Ro nI g Ep r o d u c t i o ni nt h e
plasma induced by mite cream in NC/Nga mice. As shown
in Figure 3(b), plasma IgE levels in the HIR group were
signiﬁcantlyreducedcomparedtothoseofthecontrolgroup.
These results indicate that HIR had a signiﬁcant suppressive
eﬀect on IgE production in plasma in the NC/Nga mice (∗P
< .05comparedwiththePBSgroup. #P < .05comparedwith
the base group) (Figure 3(b)).
3.4. HIR Inhibited the Elevation of Th2-Related Cytokines in
Serum and Lyphocytes. The eﬀects of HIR on the regulatory
cytokines related to AD, the cytokine levels for IL-4, IL-5,
and IL-13 were quantiﬁed by ELISA. As shown in Figure 4,
the levels of IL-4, IL-5, and IL-13 were signiﬁcantly down4 Clinical and Developmental Immunology
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Figure 2: Progression of clinical dermatitis score for diﬀerent intervention groups during the 4 weeks treatment period. Clinical ﬁndings
werescoredat1-weekintervals.(a)RepresentativeclinicalfeatureofNC/Ngamiceskin.(b)HIRtreatmentsigniﬁcantlyloweredtotalclinical
severity scores. Data shown are mean ± S.D. of changes in total clinical dermatitis scores for face, ears, nose, and back. HIR: Hirsutenone,
DEX: dexamethasone, Base: Baseline, HDC: hydrocortisone cream, INJ: injection, APP: application. ∗P < .05 compared with the PBS group.
#P < .05 compared with the Base group. n = 5/group.
regulated by HIR treatment, as compared to that of control
group. These results indicate that HIR signiﬁcantly reduced
IL-4, IL-5, and IL-13 levels in the AD-like skin lesions
(∗P < .05 compared with the PBS group. #P < .05 compared
with the base group) (Figure 4).
3.5. HIR Treatment Signiﬁcantly Down Regulated the mRNA
and Protein Expressions of Inﬂammatory Factors. To investi-
gate the eﬀect of HIR treatment on the inﬂammatory factors
relatedtoADfurther,themRNAandproteinlevelsforCOX-
2, iNOS were quantiﬁed by real-time PCR. Both COX-2 and
iNOS expressions were signiﬁcantly lower in the HIR group,
as compared to that of the control group. These results had
shownthatHIRreducedtheexpressionsofCOX-2andiNOS
in the AD-like skin lesions (∗P < .05 compared with the PBS
group. #P < .05 compared with the base group) (Figure 5).
4. Discussion
In this study, we analyzed the therapeutic eﬀect of HIR by
applying it topically and injecting to NC/Nga mice with
Dermatophagoides farina (House dust) containing cream-
induced skin lesions. Although the therapeutic eﬀects of HIR
were less than those of HDC, which was used as an active
control, topical application, and intraperitoneal injection
treatment with HIR signiﬁcantly reduced AD-like skin
lesions and clinical signs provoked by Dermatophagoides
farina, such as itching, erythema, excoriation, scaling, and
dryness. Furthermore, topical application and intraperi-
toneal injection of HIR markedly reduced epidermal hyper-
plasia, eosinophil count, and IgE levels were of AD-like skin
lesions. And Th2 cytokine levels and inﬂammatory factor
levels reduced after HIR treatment.
The presence of eosinophils in the inﬂammatory inﬁl-
trates of AD has been well established [26]. Previous studies
on atopic dermatitis suggest that skin lesions accompa-
nied by topical eosinophilia and systemic IgE elevation
are associated with Th2 cytokines (IL-4, IL-5, and IL-
13). Indeed, the elevated expressions of Th2 cytokines
have been conﬁrmed in both acute and chronic lesions of
atopic dermatitis as compared with the uninvolved skins
of patients with atopic dermatitis or those of normal
subjects [27, 28]. It is known that IL-4, IL-5, and IL-
13 are inﬂammatory cytokines that essential roles in the
activation of T cells after antigenic stimulation, and that the
skins of AD patients demonstrate Th2 cytokine overexpres-
sion, which has been reported to induce atopic responses,
such as, itching, licheniﬁcation, and chronic inﬂammation
[29].Clinical and Developmental Immunology 5
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Figure 3: Changes in eosinophil counts and IgE levels before-to-after HIR treatment. Numbers of eosinophils reduced after HIR treatment.
HIR signiﬁcantly reduced plasma IgE levels. Data are shown as mean ± S.D. HIR = Hirsutenone, DEX = dexamethasone, Base = Baseline,
HDC = hydrocortisone cream, INJ = injection, APP = application. ∗P < .05 compared with the PBS group. #P < .05 compared with the Base
group. n = 5/group.
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Figure 4: Changes in cytokine levels after HIR treatment. HIR signiﬁcantly decreased the levels of IL-4 and IL-5 in the AD-like skin lesions
of NC/Nga mice, but IL-13 levels were not signiﬁcantly decreased. Analyses were repeated at least three times. Data are mean ± S.D. HIR:
Hirsutenone, DEX: dexamethasone, Base: Baseline, HDC: hydrocortisone cream, INJ: injection, APP: application. ∗P < .05 compared with
the PBS group. #P < .05 compared with the Base group. n = 5/group.
In our preliminary studies, we found that Dermatoph-
agoides farina-treated NC/Nga mice showed progressive
increases in total IgE during experimental period. Further-
more, in a separate experiment, total plasma IgE levels
were found to be signiﬁcantly elevated in Dermatophagoides
farina-treated NC/Nga mice (data not shown).
Therefore, we devised an NC/Nga mice skin lesion
m o d e lb yr e p e a t e d l ya p p l y i n gDermatophagoides farina to
investigate the clinical eﬃcacy and the associated mechanism
underlying the therapeutic eﬀect HIR.
Several reports have shown that natural immune mod-
ulators in herbal derivatives have therapeutic eﬀects on AD
and that HIR reduces the productions of Th1 and Th2
cytokines levels [13, 14, 30–32]. Accordingly, we investigated
whether HIR modulates immune reaction in Dermatopha-
goides farina-treated NC/Nga mice. Our results show that6 Clinical and Developmental Immunology
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Figure 5:(a)COX-2andiNOSexpressionsinAD-likelesions.(A)Real-timeRT-PCR.(b)Westernblots.Columnsshowmeansandstandard
deviations. The analyses were repeated at least three times. Data are mean ± S.D. HIR: Hirsutenone, DEX: dexamethasone, Base: Baseline,
HDC: hydrocortisone cream, INJ: injection, APP: application. ∗P < .05 compared with the PBS group. #P < .05 compared with the Base
group. n = 5/group.
HIR does suppress the development of AD-like skin lesions
inNC/Ngamice.Furthermore,wefoundthatthesuppressive
eﬀects of HIR on these changes were paralleled by a decrease
in total plasma IgE level, and that this might be due to the
down-regulation of Th2 cytokines. It is also possible that the
inhibition of mast cell inﬁltration and degranulation in skin
by HIR reduces expressions of Th2 cytokines in serum and
spleen.
Recently, innate immunity has been suggested to play an
important role in the pathogenesis of AD [33, 34]. Nitric
Oxide plays a role in vasodilation, neurotransmission, blood
coagulation, and immune regulation. Furthermore, iNOS is
a major producer of NO when it is activated by various
cytokines or bacterial lipopolysaccaride (LPS). Therefore,
one of the methods used to examine the anti-inﬂammatory
activity of a compound is to measure its suppressive eﬀects
on the synthesis of iNOS [35]. COX-2 is markedly expressed
in inﬂammation-related cells in response to stimulations by
cytokines.
In summary, we show here that HIR inhibits the devel-
opment of AD-like skin lesions in NC/Nga mice induced
by the repeated application of mite. The topical application
and intraperitoneal injection of HIR could improve AD-like
skin lesions in NC/Nga mice by inhibiting IgE, eosinophil
count, or other Th2-related cytokines and inﬂammatory
factors.Taken together, our ﬁnding suggestedthat the topical
application and intraperitoneal injection of HIR may be a
novel approach to the treatment of AD.
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